Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
| Autor: | Alice B. Gottlieb, Carrie L. Wagner, Ahsan A. Abdulghani, Pat Romano, Salman Masuda, Umesh Chaudhari, Lisa T. Dooley, Adedigbo A. Fasanmade, Rallapalli Ramamurthi |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent T-Lymphocytes medicine.medical_treatment Dermatology Gastroenterology Psoriasis Area and Severity Index Psoriasis Internal medicine Humans Medicine Aged Chemotherapy Tumor Necrosis Factor-alpha business.industry Antibodies Monoclonal Immunotherapy Middle Aged medicine.disease Immunohistochemistry Infliximab Clinical trial Rheumatoid arthritis Immunology Tumor necrosis factor alpha Dermatologic Agents business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 48:68-75 |
| ISSN: | 0190-9622 |
| DOI: | 10.1067/mjd.2003.10 |
| Popis: | Objective: Infliximab monotherapy provided a rapid and high degree of clinical benefit in patients with moderate to severe psoriasis in a previously conducted trial. Herein we describe the pharmacodynamic and pharmacokinetic results observed in this clinical trial. Methods: Patients with psoriasis received 5 or 10 mg/kg of infliximab or placebo at weeks 0, 2, and 6. Immunohistochemical analysis of lesional (weeks 0, 2, 10) and nonlesional (week 0) biopsies was conducted. Median infliximab half-life and peak serum concentrations over time were calculated. Results: Infliximab immunotherapy resulted in rapid and dramatic decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques; these changes preceded maximal clinical response. Infliximab concentrations were maintained above the detection limit (0.1 mg/mL) in the majority of patients through week 14. Conclusion: The clinical and immunohistologic data demonstrate a pivotal role for tumor necrosis factor-α in the pathogenesis of psoriasis and support further development of drugs targeting tumor necrosis factor-α. (J Am Acad Dermatol 2003;48:68-75.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect